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Serine phosphorylation of insulin-like growth factor 
binding protein- 1 (IGFBP- 1) has been shown to alter 
its  affinity for the insulin-like growth factors (IGF-I 
and IGF-11) and to modify its capacity to modulate 
cellular responses to the IGFs. Because of this, we 
determined the sites of serine phosphorylation. Puri- 
fication of 3zP-labeled IGFBP-1 was followed by diges- 
tion with trypsin and endoproteinase Glu-C and radi- 
osequencing of labeled peptides. Three serines were 
found to be phosphorylated, with Ser’O’, Ser”’, and 
SerlBg containing 70%, 5%, and 25% of the incorpo- 
rated 32P,  respectively. A mutated IGFBP- 1, substitut- 
ing alanine for serine at positions 98 and 101, was 
expressed in CHO cells. On nondenaturing gels, the 
wild  type protein migrated as  five isoforms (one non- 
phosphorylated and four phosphorylated). However,  in 
the mutated protein, the most rapidly migrating band 
(a phosphorylated form) was not present. The cells 
containing the mutated cDNA incorporated 60% less 
32P into immunoprecipitable IGFBP-1. The mutated 
protein had a %fold reduction in affinity for IGF-I 
compared to the wild  type protein. We conclude that 
Ser’O’ represents the major site of phosphorylation 
containing 63% of the total 32P incorporated and that 
phosphorylation of Ser’Ol is important for maintenance 
of high affinity binding for this growth factor. 
The insulin-like growth factors, IGF-I  and -11,’ are present 
in  extracellular fluids bound to specific high affinity binding 
proteins (1, 2). Our laboratory has previously demonstrated 
that during purification of IGFBP-1 from human amniotic 
fluid two forms were identified following anion exchange 
chromatography. One form is capable of potentiating the 
effects of IGF-I on cell growth (3) while the  other is inhibitory 
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(4). Both forms have the same amino acid sequence. In 
subsequent  studies, two groups of investigators have shown 
that IGFBP-1 is phosphorylated on serine residues (5, 6). 
Serine phosphorylation results in a 6-fold increase in the 
affinity of IGFBP-1 for IGF-I.  Furthermore, phosphorylation 
appears to account for the major difference between the two 
isoforms of IGFBP-1, since the stimulatory form of IGFBP-1 
is mostly nonphosphorylated. Likewise, recombinant bacte- 
rial derived IGFBP-1, which is nonphosphorylated ( 5 ) ,  can 
potentiate  IGF-I action  in accelerating wound healing (7). In 
contrast,  IGFBP-1  that is purified from HepG2 cells is pre- 
dominantly phosphorylated (5) and inhibits  IGF-I-stimulated 
growth in chondrocytes (8). Frost and Tseng (6) have shown 
that in proliferative phase  endometrium, IGFBP-1 is secreted 
as a dephosphorylated form, whereas during the secretory 
nonproliferative phase, the endometrium  secretes  a form of 
IGFBP-1  that is heavily phosphorylated. To date, the only 
other  post-translational modification reported for IGFBP-1 
is the capacity of IGFBP-1 purified from amniotic fluid to 
form disulfide-linked multimers (9). Therefore, phosphoryla- 
tion may be an  important post-translational modification that 
regulates the capacity of IGFBP-1  to modulate IGF bioactiv- 
ity. These studies were undertaken to determine the  site(s) of 
phosphorylation  in IGFBP-1  and  to determine if mutation of 
a major site of phosphorylation results in an alteration in 
affinity for the growth factor. 
MATERIALS AND METHODS 
Chinese hamster ovary cells (CHO-K1) cells were obtained from 
the American Type  Tissue Collection. Rabbit antiserum for human 
IGFBP-1 was prepared as previously described (10). [32P]Orthophos- 
phoric acid (8500-9120 Ci/mmol) was purchased from Du Pont-New 
England Nuclear. Polyvinylidene difluoride (PVDF) transfer mem- 
branes were obtained from Millipore. Phenyl-Sepharose CL4B was 
purchased from Pharmacia LKB Biotechnology Inc. The reverse 
phase C-4 (0.46 x 3 cm) and C-8 (0.46 X 25 cm) HPLC columns were 
purchased from Vydac (Hespernia, CAI. The (2-18  (0.46 X 10 cm) and 
DEAE 5PW columns were purchased from Waters Associates. Ace- 
tonitrile, gel-coded silver stain kits, and trifluoroacetic acid were 
purchased from Pierce Chemical Co. SDS and Vent polymerase were 
obtained from Bethesda Research Laboratories (Gaithersburg, MD). 
Tissue culture plates were purchased from Falcon LabWare Division, 
Becton-Dickinson (Oxnard, CA). a-Modified Eagle’s minimal essen- 
tial medium, phosphate-free Eagle’s minimal essential medium, non- 
essential amino acids, gentamicin, and fetal bovine serum were pur- 
chased from Grand Island Biological  Co. Recombinant human IGF-I 
was obtained from Bachem, Inc. lz5I-IGF-I (150-250 pCi/wg) was 
prepared by a previously described method (23). Agarose (Seakem) 
was obtained from FMC BioProducts. Reagents used in cDNA se- 
quencing were purchased from U. S. Biochemicals, and reagents and 
the thermocycler used in the polymerase chain reaction (PCR) were 
obtained from Perkin-Elmer Cetus Instruments. [cx-~*P]~CTP and 
the ECL chemiluminescence detection system were purchased from 
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Amersham Corp. The Bluescript plasmid was obtained from Strata- 
gene. Trypsin  treated with ~-(tosylamido-2-phenyl)ethyl chloro- 
methyl ketone was from Worthington Biochemical. Calf intestinal 
alkaline phosphatase and endoproteinase Glu-C (from Staphylococcus 
aureus V8) were purchased from Boehringer Mannheim. DNA restric- 
tion endonucleases were purchased from Promega. All other chemi- 
cals except those listed were purchased from Sigma. Sequelon discs 
were obtained from Milligen. 
Tissue Culture-CHO cells were maintained in a-modified Eagle's 
minimal essential medium containing 10% fetal bovine serum and 50 
rg/ml gentamicin. An expression vector containing the cDNA encod- 
ing human IGFBP-1 was constructed by ligating a human IGFBP-1 
cDNA (11) into  a PUC18-derived plasmid (pNUT, a gift of Richard 
Palmiter, University of Washington) as previously described (5). 
Transcription of the cDNA was driven by a mouse metallothionine 
promoter utilizing polyadenylation signals and insertion  sites derived 
from the human growth hormone gene. pNUT contains the gene for 
dihydrofolate reductase driven by an SV-40 promoter allowing selec- 
tion of successfully transfected cells with methotrexate. CHO cells 
were transfected with the expression vector by calcium phosphate 
precipitation followed by glycerol shock (12). Stable methotrexate- 
resistant cell lines were established by passaging in dialyzed serum 
and by increasing the concentration of methotrexate  in the medium 
at regular intervals. The cell line designated CHOBP1-D6 secreting 
the greatest amount of human IGFBP-1 was used as a source of 
phosphorylated IGFBP-1 in all of the experiments. The cell line 
designated CHOBP1-SA 98-101-B contained the same expression 
vector with the serine to alanine mutations described below. After 
selection, both cell lines were stably  maintained in a-modified Eagle's 
minimal essential medium supplemented with 10% dialyzed fetal 
bovine serum and 50 p~ methotrexate. 
Purification of Radiolabeled IGFBP-Radiolabeled conditioned me- 
dium was prepared by labeling each of the two transfected cell lines, 
grown to confluency in 175-cm2 tissue culture dishes. The cultures 
were rinsed with phosphate-free Eagle's minimal essential medium 
containing 0.05% bovine serum albumin (BSA) and nonessential 
amino acids and  then incubated for 16 h in the same media to which 
50 pCi/ml [32P]orthophosphate was added. Following this interval, 
conditioned medium  was harvested and centrifuged and diluted with 
an equal volume of 0.05 M NaHP04, 2 mM EDTA, 0.1 M NaCI, pH 
6.6. The solution was then loaded onto an IGF-I affinity column 
which had been prepared by linking IGF-I to Sepharose, as described 
previously (13). After sample loading, the column was washed with 
the loading buffer until absorbance (280 nm) returned to baseline. 
The proteins were eluted with 0.5 M acetic acid. This solution was 
applied directly to a HPLC C-4 column (0.46 X 3  cm).  A single peak 
containing the radiolabeled protein was eluted using a  linear aceto- 
nitrile gradient from 0-100% in 0.4% trifluoroacetic acid. Total 
recovery of 32P-labeled IGFBP-1 after these  steps varied between 80 
and 90%. Material eluting from the final peak was proven to be 
IGFBP-1 by immunoblotting. The final product (60 pg)  was denatured 
and reduced in the presence of 5 M guanidine HCl and 0.1 M dithio- 
threitol,  pH 8.6, for 90 min at 37  'C. Alkylation was then performed 
by adding iodoacetic acid for a final concentration of 0.11 M and 
incubating the mixture in the dark for 1 h at 22 "C. The alkylated 
protein was separated from these reagents by rechromatographing it 
over the reverse phase HPLC (C4) column as described previously 
except that  the linear gradient was extended to 40 min. To obtain 
tryptic peptides, the radiolabeled intact protein that had been  reduced 
and alkylated was incubated with 2  units/ml bovine trypsin  in 0.13 
M ammonium bicarbonate, pH 7.8, at 37 "C for 3 h. The  pH of the 
solution containing the cleavage products was immediately adjusted 
to  pH 6.0 with acetic acid, then diluted in an equal volume of 0.04% 
trifluoroacetic acid and applied to a reverse phase  HPLC, C-8 column. 
Nine peaks were eluted using a  linear  acetonitrile  gradient from 0 to 
70% over 60 min, and  the amount of 32P in each peak was quantitated. 
An aliquot of each of the  three peaks containing radioactivity (frac- 
tions 19,32, and 34) was sequenced by Edman degradation to deter- 
mine the location of serine residues, using an Applied Biosystems 
Model 470A Sequencer as described previously (13). In addition, the 
material that was not retained by the  C-8 column was reapplied to a 
HPLC, C-18 column. Six peaks were eluted, using a Iinear gradient 
from 0-100% acetonitrile over 40 min, but only one contained a 
radiolabeled peptide, and  this peptide was also sequenced. The frac- 
tion from the tryptic digest containing the greatest amount of radio- 
activity (fraction 34) was concentrated by lyophilization, incubated 
with 4.0  pg  of staphylococcal endoproteinase Glu-C reconstituted  in 
0.25 M ammonium carbonate, pH 7.8, and incubated for 18 h at room 
temperature. The  pH of the solution containing the cleavage products 
was adjusted to  pH 6.0 with 1 M acetic acid, and  the peptides were 
separated using a reverse phase HPLC (C-18) column as previously 
described (14) and sequenced. In an additional experiment, endopro- 
teinase Glu-C digestion was performed using the intact reduced and 
alkylated protein. The resultant peptides were separated as described 
previously and sequenced by Edman degradation (13). To identify 
the sites of phosphorylation, the 32P-labeled peptides were subjected 
to manual radiosequencing by the method of Sullivan and Wong (15). 
First, the peptides were applied to arylamine-Sequelon discs and 
covalently attached by incubation of the disc in  a solution of  1.0 M 4- 
morpholineethanesulfonic acid, pH 5.0, for  30 min at room tempera- 
ture. The disc was then extracted five times with neat trifluoroacetic 
acid at  50 "C. Each peptide was subjected to repetitive cycles of 
manual Edman degradation, and  the amount of 32P bound and re- 
leased from the disc was determined after each degradation cycle. 
Three radiolabeled peptides from the endoproteinase Glu-C digests 
and two  from the tryptic digest were analyzed using this method. The 
endoproteinase Glu-C peaks numbered 8,9,10,11,12,22,24,25,  and 
29 (Fig. 1) were sequenced by Edman degradation. Some of these 
contained no radioactivity, but were sequenced to identify the posi- 
tions of the serines that were not labeled. 
Purification of IGFBP-1-To assess the electrophoretic properties 
and binding capacity of  wild type and [Ala98~10']IGFBP-1, the proteins 
secreted by the transfected CHO cells were purified. Approximately 
200  ml  of serum-free conditioned medium  was collected and used to 
purify each protein. The medium was loaded onto a 2.0 X 4.4-cm 
phenyl-Sepharose (CL-4B) column that had been previously equili- 
brated with 0.05 M sodium phosphate, 0.1 M NaCl, 2 mM EDTA, pH 
6.6. After sample loading, the column was  washed with the equilibra- 
tion buffer until the absorbance (A280 ",.J returned to baseline. The 
proteins were eluted using a 0 to 15% acetonitrile gradient in 0.05 M 
NaHPO,, 2 mM EDTA, pH 6.6, over 30 min (16). The fractions 
containing IGFBP-1 were concentrated by lyophilization and loaded 
onto an  IGF affinity column. The remaining purification steps were 
as described for radiolabeled IGFBP-1. Purity was determined by 
SDS-PAGE with silver staining (17). IGFBP-1 secreted by HepG2 
cells was purified as previously described (5). The protein content of 
the purified forms of IGFBP-1 was determined by radioimmunoassay 
Preparation of [Ala98J01]IGFBP-l Expression Vector-Two muta- 
tions (SerS8 and Ser"' to alanine) were introduced into human 
IGFBP-1 using the PCR strategy described by Higuchi (18). A 26- 
base DNA oligonucleotide (5"GGAATTCC CTG GAG ATG TCA 
GAG GTC-3', arbitrarily designated GW19), and a 26-base oligonu- 
cleotide (5"GGAATTCC CAT CTG GTT TCA GTT  TTG-3', desig- 
nated GW20)  were  designed as outside primers. These primers (GW19 
and -20) each had 18 bases that were complementary to  the IGFBP- 
1 sequence (14) at bases 118-135 in the 5' to 3' orientation and bases 
909-892 in the 3' to 5' orientation, respectively, and each contained 
an additional 8-base  pair sequence that contains an EcoRI restriction 
site (italicized). Two 29-base primers  (5'-CCT GAA GCC CCA GAG 
GCC ACG GAG ATA AC-3', designated GW21) and (5' AT CTC 
CGT GGC CTC TGG GGC TTC AGG GCT 3', designated GW22) 
were designed to be complementary to  the IGFBP-1 sequence at bases 
481-509 in the 5' to 3' orientation and bases 506-478 in the 3' to 5' 
orientation, respectively, except that they  contained  mutations that 
change amino acids 98 and 101 from serine to alanine (mutations 
italicized). 
By using GW19 with GW22 and GW20 with GW21 in separate 
PCR reactions with the wild type IGFBP-1 cDNA ligated into pBS 
as a  template, we amplified 392- and 432-base pair fragments, respec- 
tively. To obtain  those products, 5 ng of template was amplified by 
PCR  in  a 50-pl reaction, containing  10 mM KCl, 10 mM (NHI)PSOI, 
20 mM Tris-HC1, pH 8.8, 2 mM MgSO,, 0.1% Triton X-100,  0.1  mg/ 
ml BSA, 0.8 mM concentration of each dNTP, 0.1 pM concentration 
of each primer. The reaction mixture was  covered with mineral oil 
and heated for 5 min at 97 'C, and 1 unit of Vent DNA polymerase 
was added. The first 10 cycles were performed with a denaturing 
temperature of 97 "C. The remaining 21 cycles were done with a 
denaturing  temperature of 95 "C. Annealing and extension tempera- 
tures were 55 "C and 72 "C, respectively, in all cycles. 
The two DNA fragments that were prepared were analyzed and 
purified as described previously (19). These fragments each extended 
from the outside primers to  the regions of the mutations, where they 
each  contained the Alag8*'0' substitution and overlapped 26 bases. The 
products were then mixed together in equal amounts (100 ng each), 
and PCR was performed under reaction conditions as described above, 
of IGFBP-1 (10). 
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using primers GW19 and GW20. Twenty-one cycles were completed 
with denaturing, annealing, and extension temperatures of 97 "C, 
50  "C, and 72 "C, respectively. 
The final  product extended the length of the  IGFBP-1 cDNA (795 
base pairs, including the  entire protein coding region) and contained 
Alag8J01 mutations and EcoRI sites a t  both ends. It was digested with 
EcoRI and gel-purified as described previously (19). The overhangs 
were then filled in with the Klenow fragment of DNA polymerase I 
to create  blunt  ends  in  a 4.0-p1 reaction volume containing 50 mM 
NaC1, 10 mM Tris-C1, pH 7.5, 10 mM MgC12, 1 mM dithiothreitol, 
0.05 mM dATP, 0.05 mM dTTP,  and 2.5 units of Klenow fragment. 
After heat inactivation for 10 min at 70 "C, the DNA was ligated 
directly into  pNUT, which had been linearized with SmI  and de- 
phosphorylated (19). The blunt end ligation was performed at  16 "C 
with a  vector-to-insert molar ratio of 1:4. Ligation, transfection of 
Escherichia coli (strain DH-~cI), and analysis of clones was performed 
as described previously (19). 
The enzymes used for determining  orientation of the inserts were 
EcoRI/BamHI, and  this was carried out  as previously described (19). 
The clones containing the correctly oriented  inserts were sequenced 
using the dideoxy sequencing method (20). The final product con- 
tained the correct mutation while the rest of the sequence was 
identical with the sequence published for human IGFBP-1 (11). A 
clone containing the correct sequence in pNUT was transfected into 
CHO cells, and  the  IGFBP-1 expressing clones were selected with 
methotrexate as described above. 
Immunoprecipitation of Phosphorylated Products-To determine 
the degree of phosphorylation in wild type and mutated  IGFBP-1, 
each of the transfected cell lines was incubated in phosphate-free 
Eagle's minimal essential medium containing 50 pCi of [3ZP]ortho- 
phosphate for 6 h. Duplicate wells were treated identically except 
that 32P was omitted and  the amount of IGFBP-1 contained  in the 
conditioned media was determined by radioimmunoassay (10).  These 
results were used to estimate the volume of 32P-labeled conditioned 
media that contained 100 ng of IGFBP-1, and this volume was 
transferred to siliconized tubes. The volume in each  tube was adjusted 
to 1.0 ml with a buffer containing 30 mM Na2P04, pH 7.5, 50 mM 
sodium fluoride, 10 mM EDTA, 0.1% BSA, 0.01% Tween 20, and 1.0 
pl of rabbit polyclonal anti-human IGFBP-1  antiserum was added. 
After overnight incubation at 4 "C, 8 pl of ovine antisera to rabbit 
IgG  was added to each tube, and they were incubated for 1 h at 4 "C, 
followed  by the addition of 2 pl of normal rabbit serum and incubation 
for a 1 h more. Antibody-bound IGFBP-1 was separated by centrifu- 
gation at 8000 X g for 20 min. The immunoprecipitated pellets were 
washed three  times, dissolved in Laemmli sample buffer (containing 
1% SDS and 0.1 M dithiothreitol), and boiled for 10 min. The 
immunoprecipitated proteins were resolved by 12.5% SDS-PAGE, 
transferred to PVDF filters, and subjected to autoradiography. In 
order to confirm that equivalent amounts of [Ala98*101]IGFBP-1 and 
wild type IGFBP-1 were present on the filters, they were immuno- 
blotted using a 1:lOOO dilution of anti-IGFBP-1 antisera. The immune 
complexes were detected using chemiluminescence with an Amer- 
sham  ECL  substrate according to  the manufacturer's directions. 
Nondenuturing Gel Electrophoresis-In order to separate nonphos- 
phorylated IGFBP-1 from phosphorylated forms, nondenaturing 
PAGE was performed as previously described (5). Briefly, a discon- 
tinuous buffer system was used at a reduced pH (8.3) compared to 
the Laemmli system and with an acrylamide concentration of 10% in 
resolving gel and 4% in the stacking gel. The sample buffer and both 
the stacking and nonstacking gels contained n-octyl glucoside at 20 
mM. Electrophoresis was performed at 25 "C with tap water cooling. 
The proteins were transferred to PVDF membranes by electro- 
blotting, and  the transfer membranes then were subjected to autora- 
diography (in  the case of 32P-containing samples) or immunoblotting 
as previously described (5). 
Anion Exchange Chromatography-IGFBP-1 isoforms were sepa- 
rated using anion exchange chromatography. Wild type or mutant 
IGFBP-1 (25 fig) were diluted in equilibrating buffer (20 mM 
(NH&CO$, pH 8.2) and loaded onto the DEAE-anion exchange 
column. Protein absorbance was monitored at 214 nm. After the 
absorbance returned to baseline, isoforms of IGFBP-1 were eluted 
with buffer B (20 mM (NH&CO3, 1 M NaC1, pH 6.8) using a  linear 
gradient to 12% B over 10 min, followed by a  linear gradient to 25% 
B over the next 30 min and a final 10-min linear gradient to 100% B. 
IGFBP-1 eluted between 19 and 28% B, and these fractions were 
analyzed for variably phosphorylated isoforms by nondenaturing gel 
electrophoresis. 
Assay of IGFBP-I Binding of IGF-I-To determine the binding 
affinities of the phosphorylated and nonphosphorylated IGFBP-1, 
Iz5I-IGF-I was incubated with wild type IGFBP-1 from CHO cells, 
IGFBP-1 purified from the HepG2 human hepatoma cell-conditioned 
IGFBP-1 from CHO cells and 8 rg of [AlaSB~'"]IGFBP-1 were de- 
medium, or [Ala98.101]IGFBP-1. In one experiment, 8 pg  of wild type 
phosphorylated by exposure to 144 units of alkaline phosphatase in 
1.0 ml of buffer (0.05 M Tris-HC1, pH 8.5, 0.1 mM EDTA, 1 mM 
MgC12, 0.5 mM ZnC12) for 16 h at 37 "C, and  the reaction products 
were purified by reverse phase HPLC (C-4 column). Ten ng of each 
of the purified forms of IGFBP-1 were added to 0.25 ml of binding 
assay buffer containing 0.1 M HEPES, 44 mM sodium phosphate, 
0.01% Triton X-100, 0.1%  BSA, pH 7.0, in the presence of unlabeled 
IGF-I (0-100 ng/ml). The Iz5I-IGF-I that was bound was separated 
from unbound by precipitation in 12.5% polyethylene glycol (4). 
Nonspecific binding was determined in the presence of 1 pg/ml IGF- 
I and constituted less than 15% of the bound radiolabeled material. 
RESULTS 
To determine the site of serine phosphorylation, wild type 
CHO cells were incubated with [32P]orthophosphate,  and  the 
radiolabeled, secreted protein was purified to homogeneity. 
The pure product was reduced and alkylated then exposed to 
trypsin,  and the released peptides were separated by HPLC. 
Three radiolabeled peaks (fractions 19, 32, and 34)  were 
detected containing 2, 10, and 65% of the  total radioactivity, 
respectively. Amino acid sequence analysis showed that frac- 
tions 32 and 34 had the same N-terminal sequence. Fraction 
19 was completely sequenced and contained 2 serines at 
positions 169 and 174 (Table  I). This experiment was repeated 
three times, and each time fraction 19 contained radioactivity, 
but it was consistently <2% of the total incorporated 32P. 
However, approximately 23% of the  total radiolabeled protein 
did not adhere to the HPLC C-8 column. When this fall- 
through  material was rechromatographed on a C-18 column, 
a single radiolabeled peak was detected. This peptide was 
sequenced and shown to contain the same N-terminal se- 
quence as fraction 19 (Table  I). Radiosequencing of the fall- 
through peptide showed that 80% of the  total radioactivity 
was released from the filter when S e P 9  was  cleaved  from the 
peptide. This strongly supports that serine 169  is phosphoryl- 
ated  and is a major site of phosphorylation in IGFBP-1 ( i e .  
25% of the  total 32P incorporated). Because fraction 34,  which 
contained >70% of the total radioactivity, contained  9 serines, 
endoproteinase Glu-C digestion was performed, and  the  en- 
doproteinase Glu-C digestion products were further purified 
by HPLC. Four radiolabeled peaks were obtained (Fig. 1). All 
four were N-terminally sequenced and contained serine resi- 
dues. Three were subjected to radiosequencing. One peak 
(fraction 12) was shown to contain the Serg5-Pro-Glu-SerSs- 
Pro-Glu-Ser"'-Thr-Glu sequence at positions 95-103, and 
radiosequencing showed that  the serines at positions 95 and 
98 were not labeled. In contrast, the serine at position 101 
was shown to have releasable radioactivity after manual Ed- 
man degradation. Fraction 11 also contained the Ser''' as  its 
only serine and was intensely labeled. These two peptides 
containing Ser"' (Fig. 1, fractions 11 and 12) had >85% of 
the radioactivity in the tryptic fraction 34. This  supports the 
conclusion that Ser"' is a major site of phosphorylation in 
IGFBP-1.  Fraction 24 from the  HPLC column of the endo- 
proteinase Glu-C digest contained <8% of the radioactivity. 
It had only a single serine residue at position 119. This 
indicates that serine 119  is definitely labeled but represents a 
minor site of phosphorylation. Fraction 29, which  was labeled, 
contained  a mixture of two sequences, one of which contained 
serine 119. Fraction 25 did not contain radioactivity and 
contained  serines 124,131, and 136, suggesting that they were 
not labeled. Fraction 8 was minimally (<2%) labeled and 
contained Sers3 and S e P .  The phosphorylation state of 
serines  83  and 86 was further analyzed in a  separate digestion 
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TABLE I 
IGFBP-1 peptide sequences 
The amino acid sequences for the  three 32P-labeled tryptic peptides that eluted from the  HPLC C-8 column and for the 32P-labeled peptide 
isolated from the fall-through  material of this column are shown in the upper panel. The  first 15 amino acids of peptide 19 and  the first 24 
amino acids of peptide 32 were determined by sequencing. The lower panel shows the amino acid sequences for eight  peptides that were 
isolated from the digestion of the  tryptic peptide  in  fraction 34 of the upper panel. Peptides  containing significant amounts of 32P are marked 
with an asterisk. The serine residues that were determined to be PhosRhorvlated are underlined. 
Tryptic  peptides 
~~ 
Fraction  Sequences 
Fall through* " ' A Q E T S G E E I S K  
32* " G Q G A C V Q E S D A S A P H A A E A G S P E S P E E j T E  
E L L D N F H L M A P S E E D H S I L W D I S T Y D G S K  
19* " ' A Q E T S G E E I S K F Y L P N C N K  
34* " G Q G A C V Q E S D A S A P H A A E A G S P E S P E E j T E T E E  
EndoDroteinase G1u-C DeDtides 
8 8 3 S D A S A P H A A E  
9 7 5 G Q G A C V Q E  
12* ' 3 A G S P E S P E E j T E I T E  
11* " ' S T E I T E E E  
22 " ' L L D N F H L M A P S E E  
24* ' 0 7 E E L L D N F H L M A P E j E  
25 ' * ' D H S I L W D A I S T Y D G S K  
29* 1 0 s L L D N F H L M A P E j E E D H S I L W D A I S T Y D G  
0 5 IO I5 20 25 
Elution Time (min) 
FIG. 1. HPLC profile  of the endoproteinase Glu-C digested 
peptides. The tryptic peptide that contained >70% of the total 
radioadvity was subjected to digestion with endoproteinase Glu-C, 
and  the peptides that were generated were separated by HPLC  as 
described under  "Materials and Methods." The fractions that were 
sequenced are numbered, and those  containing 32P have an asterisk. 
The absorbance (Azl1 ",) is shown as a solid line, and  the acetonitrile 
gradient  is  plotted as a dashed line. No further peptides were eluted 
after the gradient reached 40% acetonitrile. 
experiment. Endoproteinase Glu-C digestion of the whole 
protein after radiolabeling followed  by N-terminal sequencing 
showed that one fraction contained a peptide with serines at  
positions 83  and 86. Direct radiosequencing of this peptide 
showed  no releasable radioactivity after Edman degradation 
of these residues. Additionally, the tryptic peptide fraction 34 
was radiosequenced and showed no releasable 32P from the 
serines at  positions 83  and 86. Continued release of amino 
acids by Edman degradation confirmed the release of radio- 
activity at  the position corresponding to Ser'O'. 
CHO cells containing an expression vector for human 
IGFBP-1 had been shown previously to secrete high  levels of 
IGFBP-1 (5). When these cells  were  labeled with [32P]ortho- 
phosphate, immunoprecipitation of an aliquot of conditioned 
medium containing 100  ng of IGFBP-1 demonstrated a 32P- 
labeled band corresponding in molecular  weight to IGFBP-1 
(Fig. 2, lune 1 ). If this immunoprecipitation was conducted in 
the presence of excess unlabeled IGFBP-1, the band intensity 
was markedly  reduced, indicating that  the immunoprecipita- 
tion was specific. In order to block phosphorylation of  Ser'O', 
this residue was changed to alanine by site-directed mutagen- 
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FIG. 2. Immunoprecipitation of S2P-labeled IGFBP-1 from 
transfected CHO cell conditioned media. CHO cells that had 
been transfected with wild type  (lanes 1 and 3) or  mutant (lanes 2 
and 4 )  cDNAs were incubated with [32P]orthophosphate as described 
under  "Materials and Methods." An equivalent amount (100 ng) of 
each radiolabeled protein was immunoprecipitated, and  the immu- 
noprecipitates were electrophoresed as described under "Materials 
and Methods" and  then transferred to PVDF filters. The figure shows 
an autoradiograph of the 32P-labeled proteins  (lanes 1 and 2) and  an 
immunoblot of the identical filter (lanes 3 and 4 ) .  The arrow denotes 
the immunoprecipitated  band corresponding to IGFBP-1. Multiple 
other immunoreactive unlabeled bands are present  in lanes 3 and 4, 
representing  rabbit immunoglobulin and other  rabbit  serum compo- 
nents in the immunoprecipitate that react with the goat anti-rabbit 
IgG conjugated to horseradish peroxidase that was used for detection. 
esis of the  IGFBP-1 expression vector.  Because of an ambi- 
guity  in the initial phosphopeptide analysis experiments sug- 
gesting that Serg8 was also phosphorylated (later disproven as 
described above), we also changed this serine to alanine during 
the mutagenesis procedure. CHO cells  were transfected with 
this construct containing base substitutions to encode ala- 
nines at  positions 98 and 101. These cells  also secreted phos- 
phorylated IGFBP-1  into  their conditioned media, and im- 
munoprecipitation of 100 ng of [Alag8*'O']IGFBP-1 demon- 
strated  a "P-labeled band of identical molecular  weight  (Fig. 
2, lune 2). However, the 32P-labeled band immunoprecipitated 
from the media containing [Ala98*'o']IGFBP-1 was  reduced in 
intensity 58% as determined by scanning densitometry, com- 
pared to  the band immunoprecipitated from  media of CHO 
cells transfected with the wild type cDNA. Immunoblotting 
followed  by scanning densitometry of the chemiluminescence- 
exposed  film  showed that 13% more total (labeled plus unla- 
beled IGFBP-1) protein was present in the [AlagR*'o']IGFBP- 
1 lane. Therefore, there was a  net decrease of 63% in 32P band 
intensity in the lane containing [Ala98~'o']IGFBP-1 compared 
to wild type IGFBP-1. These results strongly suggest that 
mutagenesis had successfully blocked phosphorylation and 
that serine 101 was a major site of phosphorylation in IGFBP- 
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1, since a 63% reduction in phosphate radiolabeling was 
detected in spite of the fact that similar amounts of protein 
were immunoprecipitated. 
To  further confirm that  the cells containing the mutated 
cDNA secreted a form of IGFBP-1 whose phosphorylation 
state had been altered, the technique of nondenaturing gel 
electrophoresis was  used. Conditioned medium from cells 
expressing the wild type protein and the [Ala98*’o’]protein 
were electrophoresed using n-octyl glucoside instead of SDS 
to permit resolution of phosphorylated and nonphosphory- 
lated IGFBP-1. As  we have  previously shown, IGFBP-1 from 
CHO  cells secreting the wild type protein resolved into five 
bands (four phosphorylated and one nonphosphorylated) 
which could be visualized by immunoblotting (Fig. 3). The 
most  rapidly migrating form, which  is  believed to be the most 
intensely phosphorylated, was easily detectable. However, 
when the media from the cells secreting [Alag8.’o‘]IGFBP-1 
were analyzed, only four bands were detected. The most 
rapidly migrating 5th band was not visualized by immuno- 
blotting (Fig. 3), and the intensity of the 4th band was 
significantly reduced. In  contrast,  the  intensity of the upper 
nonphosphorylated band was increased. This suggests that 
the most  heavily phosphorylated band migrates most rapidly 
through the gel and  that  it has been eliminated by mutagen- 
esis. HepG2 cell-conditioned media contained an increased 
amount of the most rapidly migrating bands compared to  the 
media  from  CHO  cells, suggesting that in this cell type phos- 
phorylation is  more extensive. 
The results were confirmed using anion exchange chroma- 
tography. Conditioned media from cells secreting the wild 
type and  mutant proteins were subjected to anion exchange 
HPLC using a DEAE-anion exchange column as described 
under “Materials and Methods.” The phosphorylated iso- 
forms eluted in four peaks of activity with the first peak 
containing the dephosphorylated protein and lesser amounts 
of the three phosphorylated bands. The next three peaks 
contained a mixture of the three middle bands and lesser 
amounts of the remaining two bands. The  last peak to elute 
contained the two most rapidly migrating bands. The frac- 
tions containing the [Alag8*’O’]1GFBP-1 had a major reduction 
in the amount of protein in the  last peak, indicating that loss 
of the Ser’O’ phosphorylation site resulted in an alteration in 
charge (data not shown). 
To determine the effect of phosphorylation of  Ser’O’ on the 
affinity of IGFBP-1 for IGF-I, the [Alag8*’o’]IGFBP-1 was 
purified to homogeneity as described under “Materials and 
Methods.’’  Homogeneity was proven by SDS-PAGE with sil- 
ver staining. The capacity of increasing concentrations of 
IGF-I to compete  for binding of ’251-IGF-I to [Alag8*’O’]IGFBP- 
1 and to native IGFBP-1 was compared. Scatchard plots 
obtained using each protein were linear. The slopes of the two 
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FIG. 3. Nondenaturing PAGE separation of  phosphorylated 
and nonphosphorylated forms of IGFBP-1. IGFBP-1 purified 
from the conditioned medium of the CHO cells containing the wild 
type IGFBP-1 cDNA (lane I ) ,  the [AlaSR~’O1]IGFBP-l mutant (lane 
4 ) ,  and HepG2 cells (lane 3) were subjected to PAGE in  a modified 
buffer system without SDS  as  stated under  “Materials and Methods.” 
The proteins were identified by immunoblotting. A nonphosphory- 
lated IGFBP-1  standard is shown in lane 2. The arrow denotes the 
position of the most rapidly migrating phosphorylated band which is 
present in lanes I and 3 but  absent in lane 4. 
lines were significantly different, however. The association 
constant (KO)  of the wild type protein for IGF-I was  1.9 x lo9 
M-’. In  contrast,  the K, of the [Ala98*’0’]  form  was 7.2 X 10’ 
M” or approximately 3-fold  lower  (Fig. 4). Furthermore, the 
affinity of IGFBP-1 purified from  HepG2 conditioned media, 
which contains more of the most rapidly migrating isoforms, 
was  2.5-fold greater (KO = 4.8 x lo9 M-’) than  the wild type 
CHO protein. To further confirm that serine phosphorylation 
resulted in changes in affinity, the wild type IGFBP-1  and 
[AlagR.’o’]IGFBP-l purified from CHO media were each de- 
phosphorylated with alkaline phosphatase, then repurified. 
IGF-I binding was assessed using both proteins. Scatchard 
analysis showed that dephosphorylation of  wild type IGFBP- 
1 resulted in a 6-fold reduction in affinity, whereas dephos- 
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FIG. 4. Scatchard plot of IGF-I binding to the different 
forms of IGFBP-1. IGFBP-1 was purified to homogeneity from 
CHO cells transfected with wild type (V) or mutated (0) cDNAs and 
from HepG2 cells (0). ’251-IGF-I binding and competition experi- 
ments were conducted using 4 ng/tube (HepG2) or 10 ng/tube (wild 
type and mutant) of each form of IGFBP-1 as described under 
“Materials and Methods.” The mean association constants (KO in 
M”) calculated for four experiments were  1.9 X lo9 (wild type  CHO), 
7.8 X lo8 ICHO, and 4.8 X lo9 (HepG2). 
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FIG. 5. Scatchard  plot  of  phosphorylated  and  nonphosphor- 
ylated IGFBP-1. IGFBP-1 was purified from transfected  CHO cells 
as described under  “Materials and Methods.” Both wild type IGFBP- 
1 (0, V) and [AlagR-’o’]IGFBP-l (0, V) were used in the binding assays 
as described under  “Materials and Methods” before (0 ,O)  and  after 
(V, V) dephosphorylation with alkaline phosphatase. The inset shows 
an immunoblot of a  nondenaturing gel  of the  IGFBP-1 preparations 
used in the binding assays. Shown are wild type (lanes 3 and 4 )  and 
[Ala98~10’]IGFBP-1 (lanes I and 2 )  before (lanes I and 3) and after 
(lanes 2 and 4 )  treatment with alkaline phosphatase. The arrow 
indicates the position of nonphosphorylated IGFBP-1. Lunes 2 and 4 
demonstrate that dephosphorylation of each form of IGFBP-1 was 
complete and that the serine-to-alanine mutations did not alter 
mobility of the dephosphorylated protein  in the nondenaturing gel. 
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phorylation of [Alag8~"']IGFBP-1 lowered its affinity by only 
2-fold (Fig. 5). After dephosphorylation, both the wild type 
and [Ala98.'o']IGFBP-1 proteins had identical affinities for 
IGF-I (K,  = 3.4 X lo8 "*), indicating that  the changes in  the 
affinity for IGF-I as a result were due to differences in 
phosphorylation and were not due to conformational  changes 
as a  result of the replacement of the serines with alanines. 
The fact that  the  alanine  substitutions did not  alter  protein 
conformation was confirmed by the observation that after 
dephosphorylation both  the wild type and  the  mutated pro- 
teins had  identical mobilities during  nondenaturing gel elec- 
trophoresis (inset, Fig. 5, lunes 2 and 4 ) .  
DISCUSSION 
These studies demonstrate  that  IGFBP-1 is phosphorylated 
on serine residues at  positions 101, 119, and 169. Phosphoryl- 
ation of  Ser"' accounts for greater than 60% of the  32P  that 
is  incorporated into  the protein.  Direct radiosequencing also 
showed that Ser16' was labeled and accounted for 25% of the 
3zP incorporation. Ser"' was not directly radiosequenced due 
to  the small amount (8%) of 32P incorporated, but complete 
sequencing of the labeled peptide in fraction 24 after endo- 
proteinase  Glu-C digestion showed that  it was the only serine 
present. Further indirect evidence that Ser"' is a  phosphoryl- 
ation  site is that  it is followed by a sequence that is similar to 
those following serines 101 and 169 (i.e. Ser-X-Glu). There- 
fore, we conclude that Ser"' is phosphorylated, but  it is a 
minor site of phosphorylation. Importantly, the serines a t  
positions 83, 86, 95, and 98 were definitively proven to be 
nonphosphorylated by direct radiosequencing. Likewise, se- 
quencing of several unlabeled peptides showed that several 
other serines were not labeled. We conclude that these 3 
serines  are  the  sites of IGFBP-1 phosphorylation and  that 
serines  101 and 169 account for >85% of the  total 32P that is 
incorporated. 
Direct radiosequencing showed that  the  serine  at position 
101 was a major site of phosphorylation, and  the  extent of 
phosphorylation of this residue was confirmed by mutagene- 
sis. Specifically, changing this residue to  alanine  to  prevent 
its phosphorylation  resulted in a  63%  reduction in radiolabel- 
ing of the immunoprecipitated protein.  Western blotting of 
the immunoprecipitated proteins showed that equivalent 
amounts of protein were loaded in each gel lane, and therefore 
the comparison of radiolabeled band  intensity is valid. These 
data  taken together  confirm that  serine  101 is  phosphorylated 
and  is a major site of phosphorylation in  this protein. 
Further definitive evidence that  the [Ala98~'o']IGFBP-1  con- 
tained an alteration in the degree of phosphorylation of 
IGFBP-1 was derived from two observations. First, nonde- 
naturing gel electrophoresis showed a  significant decrease in 
the two most rapidly migrating bands  containing phosphoryl- 
ated IGFBP-1 and eliminated the most rapidly migrating 
band. Reduction in the  abundance of this most rapidly mi- 
grating band indicates that  the  rate of migration through  the 
electric field is dependent upon the number of phosphate 
groups per IGFBP-1 molecule as well as site-specific changes 
in charge density. This observation supports  the hypothesis 
that different bands detected  using this technique are due to 
differences in the degree of IGFBP-1 phosphorylation and 
that removal of the most heavily phosphorylated site results 
in a mobility shift. The results do  not definitely determine 
whether this  shift is due to a change in  number of serines 
that  are phosphorylated or to  the location of specific phos- 
phoserine residues. Second, anion exchange  chromatography 
confirmed these  observations. Frost  and  Tseng  (6) have pre- 
viously shown that this technique will separate the most 
rapidly migrating bands from the slowest migrating bands. 
Separation of the isoforms of wild type IGFBP-1 showed that 
the most rapidly migrating  forms  eluted from the column at  
higher salt concentration. The  amount of this  latter peak of 
protein was reduced when [Alag8~'"]IGFBP-1 was analyzed, 
further confirming that  mutation had  resulted in a reduction 
in  the  amount of this phosphorylated isoform. 
The physiologic consequences of the mutation of Serl'' 
were significant. The [Ala98J01]IGFBP-1 mutant had  a $fold 
reduction in affinity  for IGF-I, suggesting that phosphoryla- 
tion of this  site is an  important means of enhancing IGFBP 
affinity. The  mutation of Serg8 to  alanine had no demonstrable 
effect on the  protein, since after dephosphorylation, both  the 
wild type and  the  mutant  proteins had  identical  affinities for 
IGF-I  and identical mobilities under  nondenaturing gel elec- 
trophoresis,  indicating that  the only effect of the two serine- 
to-alanine  mutations was to  prevent  the phosphorylation of 
Ser'''. Nondenaturing gel electrophoresis  is very sensitive in 
detecting differences in charge or native conformation of 
proteins, and the identical mobilities of the wild type and 
mutant  IGFBP-1 after dephosphorylation make it extremely 
unlikely that  the amino acid alterations  in  the  mutant protein 
had any direct effect on conformation. We confirmed our 
earlier observation that dephosphorylation of IGFBP-1 re- 
duces affinity for IGF-I 6-fold (5). However, preventing  phos- 
phorylation of Ser''' by mutagenesis did not completely re- 
duce the affinity of IGFBP-1  to  that of the dephosphorylated 
protein (Fig. 5 ) .  This suggests that  IGFBP-1 affinity for IGF- 
I  is increased by phosphorylation not only of  Ser"' but also 
of serines 119 and/or 169. 
Nondenaturing gel electrophoresis of IGFBP-1 purified 
from  various sources demonstrates a  correlation between the 
relative  abundance of the most rapidly migrating (and most 
heavily phosphorylated) IGFBP-1  band  and relative  affinity 
for IGF-I. When IGFBP-1 purified from the conditioned 
media of CHO cells is compared to  that of HepG2 cells, the 
HepG2 protein contains much more of the most rapidly 
migrating isoform (Fig. 3). Likewise when the affinity of the 
HepG2 IGFBP-1 is  compared to  the wild type CHO protein, 
it is consistently 2-3-fold greater (Fig. 4). Thus, the abun- 
dance of this most rapidly migrating isoform correlates well 
with  changes in the  net affinity of IGFBP-1 for  IGF-I. Phos- 
phorylation of  Ser''' is necessary for this isoform to be pres- 
ent, since it is absent  in  the [Alag8~''']IGFBP-1 mutant (even 
though at  least 2 other serines are phosphorylated), and  this 
is consistent with our observation that  the  mutant  protein 
has a lower affinity  for  IGF-I. Taken together  with the finding 
that  IGFBP-1 secreted by HepG2 cells has  the highest relative 
affinity, we conclude that both the degree of phosphorylation 
of Ser''' and  the  total number of phosphates per molecule 
contribute  to  an increase in  IGFBP-1 affinity for IGF-I. 
Our finding that  the principal site of phosphorylation is 
contained in a Ser-X-Glu-X-X-Glu-Glu-Glu seq ence and 
that two other sites contain the Ser-X-Glu sequence with 
other acidic residues located on  their C-terminal side of the 
phosphorylation site suggests that a member of the casein 
kinase family could be the kinase responsible for  phosphoryl- 
ation of IGFBP-1. Phosphorylation by casein kinase I1 de- 
pends upon acidic residues on the C-terminal side of the 
phosphorylated  serines, and  this enzyme has been reported to 
phosphorylate protein phosphatase inhibitor-2 which con- 
tains a  Ser-X-Glu sequence (21). Other known serine-threo- 
nine kinases do not recognize this motif and  neither Ser"', 
Ser"', nor Ser"j' represents  consensus  phosphorylation sites 
for other known protein kinases. We have confirmed the 
finding  reported by Frost  and  Tseng  (6)  that casein kinase I1 
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can phosphorylate IGFBP-1 i n  vitro,2 but we have not proven 
that this is the kinase in CHO cells that phosphorylates 
IGFBP-1. An important objective of future  studies will  be to 
identify the intracellular kinase since it  appears to be able to 
modulate the affinity of IGFBP-1 for IGF-I. 
In previous studies, we have demonstrated that nonphos- 
phorylated  IGFBP-1 purified from amniotic fluid is a  potent 
potentiator of IGF's effects on porcine aortic smooth muscle 
cells. Specifically, IGFBP-I added under these conditions 
potentiated smooth muscle cell response 5.5-fold, and this 
response exceeded that of 10%  human serum (3). In a recent 
in vivo assay, we demonstrated that nonphosphorylated 
IGFBP-1  potentiates wound healing in rats, leading to a 37% 
increase in wound breaking strength. There also is a 67% 
increase in hydroxyproline content reflecting increased col- 
lagen synthesis,  and histologic analysis shows that  the wounds 
that have  received nonphosphorylated IGFBP-1  plus  the IGF- 
I have increased cellularity (7). All of these responses are 
consistent with increased trophic  action of this growth factor 
being potentiated by nonphosphorylated IGFBP-1. In con- 
trast, direct addition of phosphorylated IGFBP-1 resulted in 
no increase in breaking strength or in hydroxyproline content 
(7). Therefore, phosphorylated IGFBP-1  not only appears to 
inhibit cell growth in culture,  but also appears to inhibit the 
wound healing response to IGF-I in an i n  vivo model test 
system. Potential physiological regulation of the kinase that 
phosphorylates IGFBP-1  in  situations of diminished growth 
is further substantiated by our finding that when newborn 
pigs are starved for 48 h, IGFBP-1 becomes heavily phos- 
phorylated (22). Therefore, it is possible that phosphorylated 
IGFBP-1 can act as a growth inhibitor and that metabolic 
conditions which are associated with growth inhibition result 
in increased phosphorylation of this protein. Likewise, our 
data obtained in pigs suggest that phosphorylation of IGFBP- 
1 may  be an important means for inhibiting the insulin-like 
actions of IGF-I  in response to fasting. 
In summary, our findings show that Ser''' is an important 
phosphorylation site in IGFBP-1. Phosphorylation at this 
J. I. Jones, unpublished observations. 
residue markedly alters affinity of the binding protein for the 
growth factor. Future  studies should enable us to determine 
the effect of substitutions at positions 119 and 169 on the 
functional activity of IGFBP-I,  and these  mutants may be 
useful in confirming the identity of the kinase that phospho- 
rylates IGFBP-1. 
Acknowledgments-We gratefully acknowledge the secretarial as- 
sistance of Jennifer O'Lear. We thank Ric  Ong  who conducted the 
IGF binding assays. 
REFERENCES 
1. Baxter, R. C. (1991) in Modern Concepts of Insulin-like Growth Factors 
(Spencer, E. M.,  ed) pp. 371-380, Elsevier Science Publishing Co., New 
15. Sullivan S. and Wong T. W. (1991) Anal. Biochern. 197,65-68 
16. Martin, h. d., Willetts, K .  E., and Baxter, R. C. (1990) J.  Bid. Chern. 2 6 6 ,  
4124-4130 
17. Oakley, B. R., Kirsch, D. R., and Morris, N.  R.  (1980) Anal. Biochern. 106 ,  
361-363 
18. Higuchi R. (1989) in PCR Technology: Principles and Ap licationsfor DNA 
Arnpl&ztion (Erdich H. A., ed) pp. 61-70 Stockton $res,, New York 
19. Camacho-Hubner, C., Bkby,  W .  H., Jr., Mcdusker, R. H., Wright, G., and 
Clemmons, D. R.  (1992) J .  Bud. Chern. 267,11949-11956 
20. Sanger F., Nicklen S., and Coulson, A. R.  (1977) Proc. Natl. Acad. Sci. U. 
S. A.'74,5463-5;67 
21. Pearson, R. B., and Kemp, B. E. (1991) Methods Enzyrnol. 200,62-81 
22. McCusker R.  H., Jones J. I. and Clemmons D. R. (1992) Abstracts of the 
Annual 'Meeting of t h  AAerican Society 0) Animal Science, Pittsburgh, 
PA,  August 8-1 1 
23. Svoboda, M. E., Van W k, J J , Klapper, D: G., Fellows, R.  E., Grissom, 
F.  E., and Schleuter, 8. J. (1980) Biochernstry 19,790-797 
